Atrys has consolidated its growth in the first nine months of the year, with a 9.7% increase in revenue and an 18.5% rise in EBITDA

- *Turnover reached 117.1 million euros and EBITDA 14.2 million. EBITDA from organic business grew by 40.3%*
- *Operating cash flow rose by 152.6 per cent to 11.3 million euros, driven by growth in EBITDA and greater investment discipline*
- *Oncology and Nuclear Medicine grew by 22.5% and 10.0%, respectively. Latin America grew by 28.2%, driven by Mexico, whilst Portugal saw its EBITDA increase 6.8-fold.*

16 November 2026. Atrys Health, a medical company specialising in the provision of healthcare services in oncology, telediagnostics, pathological anatomy and nuclear medicine, closed the first nine months of 2026 with a turnover of 117.1 million euros, up 9.7 per cent on the same period in the previous financial year. Oncology and Nuclear Medicine remained among the fastest-growing areas, alongside the expansion of international operations, particularly in Mexico and Portugal.

Gross profit reached 49 million euros, up 6.5 per cent, whilst EBITDA stood at 14.2 million, 18.5 per cent higher than in the same period of the previous year, with an EBITDA margin of 12.2 per cent, compared with 11.3 per cent recorded a year earlier. Excluding the accounting effects arising from the capitalisation of R&D expenditure, organic EBITDA grew by 40.3 per cent. This growth, together with greater investment discipline, boosted cash generation, with operating cash flow of €11.3 million, up 152.6 per cent.

The results also reflect the efficiency improvements stemming from the new organisational model implemented in 2026, designed to simplify the structure and strengthen management control. The measures taken have enabled a reduction in corporate staff costs and operating expenses of 15.1 per cent and 23.3 per cent respectively.

Atrys has ended the first nine months of 2026 with a solid financial structure. Following the sale of ASPY, completed in January for 145 million euros, net financial debt stood at 37.5 million at the end of September, 78.1 per cent lower than at the end of 2025. This financial optimisation also led to savings of 6.3 million euros in finance costs compared with the same period last year. The company continues to make progress in restructuring its debt to align it with the requirements of its 2026–2028 Strategic Plan.

Marian Isach, CEO of Atrys, said: “These results reflect the progress we have made in implementing our strategy and our commitment to improving profitability, generating cash flow and strengthening our healthcare capacity. The growth in our strategic areas and the efficiency improvements we are implementing enable us to approach the final stretch of the financial year with confidence that we will meet our targets, whilst maintaining our focus on providing specialised, high-quality healthcare.”

Oncology and Nuclear Medicine drive growth, with Mexico and Portugal as key markets

Oncology has continued to establish itself as one of Atrys’s main drivers of growth, with a 22.5 per cent increase in turnover and a 17.1 per cent rise in EBITDA. Meanwhile, Nuclear Medicine saw its revenue rise by 10.0 per cent and its EBITDA by 157.4 per cent, mainly driven by the

performance of its operations in Portugal. Diagnostic Imaging also continued to perform well, with revenue growth of 7.2 per cent.

En España, destacan los crecimientos de Diagnóstico por Imagen (+15,4%) y Oncología (+5,9%), junto con la evolución positiva de Medicina Nuclear, que aumentó un 6,5% sus ingresos y un 56,4% su EBITDA.

Portugal consolidated the recovery in its profitability, with a 5.7 per cent increase in turnover and EBITDA 6.8 times higher than in the same period last year, reaching 2.4 million euros, thanks to the management measures implemented and the strong performance of Nuclear Medicine, whose revenue grew by 11.9 per cent.

Por su parte, Latinoamérica aumentó sus ingresos un 28,2%, impulsada especialmente por México, donde los ingresos crecieron un 131,9% y el EBITDA un 216,5%, gracias a la consolidación del negocio de oncología médica. La apertura en octubre de un nuevo centro en Querétaro, que se suma al de Sentura, seguirá contribuyendo a reforzar el crecimiento del negocio y a mejorar la capacidad asistencial de Atrys en el país. Colombia y Perú también mantuvieron una evolución positiva, con un crecimiento conjunto del 25,7%.

Meanwhile, Latin America saw its revenue rise by 28.2 per cent, particularly driven by Mexico, where revenue grew by 131.9 per cent and EBITDA by 216.5 per cent, thanks to the consolidation of the medical oncology business. The opening in October of a new centre in Querétaro, in addition to the one in Sentura, will continue to help strengthen the business's growth and improve Atrys's healthcare capacity in the country. Colombia and Peru also performed well, with combined growth of 25.7 per cent.

Atrys maintains its targets for 2026

Following the performance recorded in the first nine months of the year, Atrys maintains its targets for 2026 as a whole, which include achieving a turnover of 156.5 million euros, an increase of 11 per cent; reported EBITDA of €20.5 million, up 34 per cent; and operating cash flow of €13.5 million, 125 per cent higher than in the previous financial year.

Today, Monday 16 November, at 10.00 am, the webcast presenting Atrys' 9M 2026 results will take place. Registration for online access must be completed via this link: https://connectstudio-portal.world-television.com/es/6abe5b12d40d111133255383/registration

About Atrys

Atrys is a healthcare company operating in seven countries, specialising in the provision of healthcare services in oncology, telediagnostics, pathological anatomy and nuclear medicine, and offering its clients clinical solutions designed to improve care and address long-term structural challenges.

Media contacts

Diana Barriga
Atrys
dbarriga@atryshealth.com
+34 649 042 525

Marta Estarellas
Roman
m.estarellas@romanrmcom
+34 663 027 941